Martin Shkreli to go toe-to-toe with new FTC chair over Daraprim price spikes

Max Gelman

Senior Editor

Much ink has been spilled over “Pharma Bro” Martin Shkreli, the entrepreneur who raised the price of a lifesaving antiparasitic more than 55-fold overnight and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Martin Shkreli to go toe-to-toe with new FTC chair over Daraprim price spikes

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

Post-Hoc: Pharma CEOs' alternative reality with Trump

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

How AI can address ongoing challenges in the life sciences industry

Mar­tin Shkre­li to go toe-to-toe with new FTC chair over Dara­prim price spikes

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Martin Shkreli to go toe-to-toe with new FTC chair over Daraprim price spikes